A5073780219- Colorectal Cancer Treatments and Studies
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Cancer survivorship and care
- Statistical Methods in Clinical Trials
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- HER2/EGFR in Cancer Research
- Advanced Causal Inference Techniques
- Ovarian cancer diagnosis and treatment
- Colorectal and Anal Carcinomas
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Topic Modeling
- Cancer Cells and Metastasis
- Natural Language Processing Techniques
- Radiopharmaceutical Chemistry and Applications
- Breast Cancer Treatment Studies
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Surgical Treatments
- Cancer therapeutics and mechanisms
- Testicular diseases and treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Advanced Breast Cancer Therapies
Inserm
2016-2025
Université de Montpellier
2016-2025
Institut de Recherche en Cancérologie de Montpellier
2015-2024
Institute for Neurosciences of Montpellier
2024
Onco Lille
2017-2023
Hôpital Saint Eloi
2023
Institut Universitaire de Recherche Clinique
2021-2023
Centre Hospitalier Universitaire de Montpellier
2017-2023
Institut Regional du Cancer de Montpellier
2014-2022
Zimmer Biomet (France)
2018-2022
To compare the quality of life (QoL) patients receiving oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) or gemcitabine as first-line chemotherapy to assess whether pretreatment QoL predicts survival in with metastatic pancreatic cancer.Three hundred forty-two performance status 0 1 were randomly assigned receive FOLFIRINOX (oxaliplatin, 85 mg/m(2); 180 leucovorin, 400 mg/m(2) bolus followed by 2,400 46-hour continuous infusion, once every 2 weeks) 1,000 weekly for 7 8...
To develop a prognostic model in patients with germ cell tumors (GCT) who experience treatment failure cisplatin-based first-line chemotherapy.Data from 1,984 GCT progressed after at least three cycles and were treated conventional-dose or carboplatin-based high-dose salvage chemotherapy was retrospectively collected 38 centers/groups worldwide. One thousand five hundred ninety-four (80%) of eligible randomly divided into training set 1,067 (67%) validation 527 (33%). Seminomas aside for...
Purpose Conventional-dose chemotherapy (CDCT) and high-dose (HDCT) may both be successfully used as salvage treatment for patients with metastatic germ cell tumors (GCTs) who experience progression first-line treatment. Patients Methods Data on 1,984 GCTs experienced after at least three cisplatin-based cycles were treated either CDCT or carboplatin-based HDCT collected from 38 centers groups worldwide. Of patients, 1,594 (80%) eligible, among the eligible 1,435 (90%) could reliably...
Abstract To our knowledge, this is the first comprehensive study on influence of several pre-analytical and demographic parameters that could be a source variability in quantification nuclear mitochondrial circulating DNA (NcirDNA McirDNA). We report data from total 222 subjects, 104 healthy individuals 118 metastatic colorectal cancer (mCRC) patients. Approximately 50,000 3,000-fold more than genome copies were found plasma mCRC patients, respectively. In individuals, NcirDNA concentration...
Purpose In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments. However, only about half treated respond to this regimen, there no clinically useful marker that predicts response. A major clinical challenge identify subset who could benefit from chemotherapy. We aimed a gene expression profile in primary colon cancer tissue predict chemotherapy Patients Methods Tumor samples 21 were analyzed...
Colorectal cancer (CRC) is one of the most common causes death throughout world. In this work our aim was to study role phosphoserine aminotransferase PSAT1 in colorectal development.We first observed that overexpressed colon tumors. addition, we showed after drug treatment, expression level hepatic metastases increased non responder and decreased patients. experiments using human cell lines, ectopic overexpression carcinoma SW480 line resulted an increase its growth rate survival....
Abstract Purpose: Circulating cell-free DNA (ccfDNA) is a valuable source of tumor material obtained from simple blood sampling that enables noninvasive analysis the genome. Our goal was to carry out multiparametric ccfDNA and evaluate its prognostic value by investigating overall survival (OS) 97 metastatic colorectal cancer patients (mCRC). Experimental Design: Qualitative parameters (determination main KRAS exon2 BRAF V600E mutations) quantitative (total concentration, mutant proportion...
Abstract Evidence suggests that lean body mass (LBM) may be useful to normalize chemotherapy doses. Data from one prospective and retrospective study were used determine if the highest doses of oxaliplatin/kg LBM within FOLFOX regimens would associated with dose‐limiting toxicity (DLT) in colon cancer patients. Toxicity over four cycles was graded according NCI Common Criteria V2 or V3 (Common Terminology for Adverse Events, National Cancer Institute, Bethesda, MD). Muscle tissue measured by...
Longitudinal analysis of health-related quality life (HRQoL) remains unstandardized and compromises comparison results between trials. In oncology, despite available statistical approaches, are poorly used to change standards care, mainly due lack standardization the ability propose clinical meaningful results. this context, time deterioration (TTD) has been proposed as a modality longitudinal HRQoL for cancer patients. As tumor response progression, we develop RECIST criteria HRQoL.Several...
Research Article9 February 2018Open Access Source DataTransparent process Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer Maya Jeitany CRBM, CNRS, University Montpellier, France Search more papers this author Cédric Leroy Novartis Institutes Biomedical Research, Postfach, Basel, Switzerland Actelion Pharmaceuticals Ltd, Allschwil, Priscillia Tosti Marie Lafitte Jordy Le Guet Valérie Simon Debora Bonenfant Bruno Robert IRCM,...
Social media dedicated to health are increasingly used by patients and professionals. They rich textual resources with content generated through free exchange between patients. We proposing a method tackle the problem of retrieving clinically relevant information from such social in order analyze quality life breast cancer.Our aim was detect different topics discussed on relate them functional symptomatic dimensions assessed internationally standardized self-administered questionnaires...
HER2-low breast cancer (i.e., HER 1+ or 2+, without gene amplification) is an emerging subtype for which very few data are available, especially within the triple-negative (TNBC) group. Our aim was to evaluate HER2 expression and its prognostic value in a large retrospective series of patients with non-metastatic TNBC (median age: 57.7 years; range: 28.5-98.6). Among 296 samples, 83.8% were 0, 13.5% 1+, 2.7% 2+ (HercepTestTM 2018 ASCO/CAP guidelines scoring). CK5/6 and/or EGFR-expressing...
Abstract The antiestrogen tamoxifen, a major endocrine therapy of estrogen receptor (ER)-positive breast cancer, is nevertheless inefficient in 30 to 40% cases for unknown reasons. We retrospectively studied 50 ER-positive primary carcinomas. All the patients had received tamoxifen as only adjuvant therapy. They were divided into two groups depending on whether they relapsed within 5 years (16 tamoxifen-resistant cases) or did not relapse (34 tamoxifen-sensitive cases). expression total ERβ...
Pouget, J-P., Santoro, L., Raymond, Chouin, N., Bardiès, M., Bascoul-Mollevi, C., Huguet, H., Azria, D., Kotzki, P-O., Pè legrin, Vivès, E. and Pèlegrin, A. Cell Membrane is a More Sensitive Target than Cytoplasm to Dense Ionization Produced by Auger Electrons. Radiat. Res. 170, 192–200 (2008).To improve radioimmunotherapy with electron emitters, we assessed whether the biological efficiency of 125I varied according its localization. A-431 SK-OV-3 carcinoma cells were incubated increasing...
We examined the feasibility of using a panel autoantibodies to multiple tumor-associated proteins as method for early detection breast cancer and, more particularly, carcinoma in situ (CIS).PPIA, PRDX2, and FKBP52 were identified early-stage autoantigens by proteomic approaches. The seroreactivity antibodies consisting these three antigens two previously described autoantigens, HSP60 MUC1, was tested on 235 samples (60 from primary patients, 82 CIS 93 healthy controls) with use specific...
Despite recent advances in the treatment of colon cancer, tumor resistance is a frequent cause chemotherapy failure. To better elucidate molecular mechanisms involved to irinotecan (and its active metabolite SN38), we established SN38-resistant clones derived from HCT-116 and SW48 cell lines. These show various levels (6- 60-fold) SN-38 display enhanced activated MAPK p38 as compared with corresponding parental cells. Because four different isoforms have been described, then studied effect...